ATE132369T1 - Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten - Google Patents

Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten

Info

Publication number
ATE132369T1
ATE132369T1 AT91401311T AT91401311T ATE132369T1 AT E132369 T1 ATE132369 T1 AT E132369T1 AT 91401311 T AT91401311 T AT 91401311T AT 91401311 T AT91401311 T AT 91401311T AT E132369 T1 ATE132369 T1 AT E132369T1
Authority
AT
Austria
Prior art keywords
producing
tetrahydropyridi
naphthylethyl
trifluoromethylphenyl
cerebral
Prior art date
Application number
AT91401311T
Other languages
English (en)
Inventor
Francois Xavier Coude
Jacqueline Fournier
Umberto Guzzi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE132369T1 publication Critical patent/ATE132369T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT91401311T 1990-05-22 1991-05-21 Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten ATE132369T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
ATE132369T1 true ATE132369T1 (de) 1996-01-15

Family

ID=9396855

Family Applications (2)

Application Number Title Priority Date Filing Date
AT91401311T ATE132369T1 (de) 1990-05-22 1991-05-21 Verwendung von 1-(2-naphthylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung von zerebralen und neuronalen krankheiten
AT94403014T ATE207747T1 (de) 1990-05-22 1991-05-21 Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94403014T ATE207747T1 (de) 1990-05-22 1991-05-21 Verwendung von vincristin zur auswertung von wirkstoffen in zentralnervensystems

Country Status (16)

Country Link
US (3) US5229389A (de)
EP (2) EP0458696B1 (de)
JP (2) JP2618115B2 (de)
KR (1) KR0181330B1 (de)
AT (2) ATE132369T1 (de)
BR (1) BR9105015A (de)
CA (2) CA2365832C (de)
CY (1) CY2283B1 (de)
DE (2) DE69132797T2 (de)
DK (2) DK0655247T3 (de)
FR (1) FR2662355B1 (de)
HU (1) HU208922B (de)
IE (1) IE911707A1 (de)
IL (3) IL98175A (de)
TW (1) TW216771B (de)
ZA (1) ZA913865B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
ES2159362T3 (es) * 1995-10-26 2001-10-01 Sanofi Synthelabo Utilizacion de la 1-(2-naft-2-iletil)-4-(3-trifluorometilfenil)-1,2,3,6-tetrahidropiridina para la preparacion de medicamentos destinados para el tratamiento de la esclerosis lateral amiotrofica.
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
DE69736976T2 (de) * 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
TR199901722T2 (xx) * 1997-02-03 2000-08-21 Sanofi-Synthelabo S.A. 1-$4-(3-Trifloro metilfenil)-1,2,3,6-tetrahidro pirid-1-il]-2-(6,7-dimetoksi naft-2-il)etan'�n n�rotropik etkisi olan ila�lar�n haz�rlanmas�nda kullan�lmas�
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
HK1001471A1 (en) 1998-06-19
ZA913865B (en) 1992-02-26
KR0181330B1 (ko) 1999-03-20
US5229389A (en) 1993-07-20
EP0655247B1 (de) 2001-10-31
CA2365832A1 (en) 1991-11-23
IL112167A0 (en) 1995-03-15
IE20011078A1 (en) 2002-03-20
CA2042974C (en) 2002-09-17
IL98175A0 (en) 1992-06-21
US5468753A (en) 1995-11-21
DE69132797D1 (de) 2001-12-06
AU636488B2 (en) 1993-04-29
EP0458696A3 (en) 1992-03-18
HU208922B (en) 1994-02-28
DE69132797T2 (de) 2002-05-29
CY2283B1 (en) 2003-07-04
EP0655247A1 (de) 1995-05-31
DE69115989T2 (de) 1996-08-22
DK0458696T3 (da) 1996-05-20
KR910019617A (ko) 1991-12-19
JP2618115B2 (ja) 1997-06-11
JPH04226917A (ja) 1992-08-17
JP2954029B2 (ja) 1999-09-27
FR2662355B1 (fr) 1994-11-10
US5270320A (en) 1993-12-14
EP0458696A2 (de) 1991-11-27
FR2662355A1 (fr) 1991-11-29
IE911707A1 (en) 1991-12-04
DK0655247T3 (da) 2002-02-18
IL98175A (en) 1996-01-19
DE69115989D1 (de) 1996-02-15
AU7713391A (en) 1991-11-28
ATE207747T1 (de) 2001-11-15
HUT59824A (en) 1992-07-28
EP0458696B1 (de) 1996-01-03
IL112167A (en) 1996-01-31
BR9105015A (pt) 1993-05-25
CA2365832C (en) 2007-08-07
JPH09132535A (ja) 1997-05-20
HU911729D0 (en) 1991-12-30
CA2042974A1 (en) 1991-11-22
TW216771B (de) 1993-12-01

Similar Documents

Publication Publication Date Title
DE69115989D1 (de) Verwendung von 1-(2-Naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur Herstellung eines Medikaments zur Behandlung von zerebralen und neuronalen Krankheiten
ATE446101T1 (de) Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
DE69524679D1 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE68908971D1 (de) Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen.
DE69204639D1 (de) Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.
ATE254172T1 (de) Verbeugende oder therapeutische mittel für die alzheimer-krankheit, eine siebtest-methode, und die menschliche tau-protein-kinase
ATE171372T1 (de) Verwendung eines antagonisten der substanz p zur behandlung von hautrötungen neurogen ursprungs
DE69233725D1 (de) Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
ATE135220T1 (de) Verwendung von 1-alpha,24(r)-dihydroxy-22(e)- dehydrovitamin-d3 zur herstellung eines arzneimittels zur behandlung der osteoporose
EP0224596A4 (de) Verwendung von aus Schisandrae Fructus extrahierten Dibenzocyclooctadien-Lignanen zur Herstellung eines Arzneimittels für die Behandlung von Leberschwäche.
ATE304861T1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
NO901303L (no) Nye benzotiopyranylaminer.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
DE3873188D1 (de) Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen.
DE69425345D1 (de) Anwendung von Selegilin in Tiermedizin
ATE334669T1 (de) Verfahren zur herstellung eines extraktes aus copalchirinde und verwendung der neoflavonoide zur behandlung von diabetes
DE59701514D1 (de) Verfahren zur bestimmung der phototoxizität und/oder photosensibilität von stoffen oder stoffgemischen sowie dessen verwendung
DE68907178D1 (de) Verfahren zur behandlung von quaternaeren oniumsalzen und dessen verwendung bei der herstellung von hexafluorpropylenoxid.
Rhoades et al. Altered organization of intercollicular pathway in bilaterally enucleated hamsters
Gilden Dual action effects of morphine on the electrical activity of the dorsal tegmentum
DE69228235D1 (de) Verwendung eines Mittels zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankung
Lehning Neuropathologic and electrophysiologic effects of organophosphorus delayed neurotoxicants on the central nervous system of the rat
DE69431320D1 (de) Verwendung von menschlichem Interferon-d zur Herstellung eines Arzneimittels zur Behandlung von Atemwegserkrankungen in Katzen
PT66587A (de) 2-dimethylcarbamoylimino-1,3,4-thiadiazolin-3-id-salze,verfahren zur herstellung diese verbindungen sowie diese enthaltende herbizide mittel
DE69001070D1 (de) Verwendung von beta-blockierungsmitteln zur behandlung der meniere-krankheit.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time